JP2021506904A - Ｃｎｓ障害の処置のための組成物および方法 - Google Patents

Ｃｎｓ障害の処置のための組成物および方法 Download PDF

Info

Publication number
JP2021506904A
JP2021506904A JP2020534302A JP2020534302A JP2021506904A JP 2021506904 A JP2021506904 A JP 2021506904A JP 2020534302 A JP2020534302 A JP 2020534302A JP 2020534302 A JP2020534302 A JP 2020534302A JP 2021506904 A JP2021506904 A JP 2021506904A
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
alkyl
compound according
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2020534302A
Other languages
English (en)
Japanese (ja)
Inventor
アルバート ジーン ロビチャウド，
アルバート ジーン ロビチャウド，
フランセスコ ジー． サリトゥロ，
フランセスコ ジー． サリトゥロ，
マリア ヘスス ブランコ−ピヤド，
マリア ヘスス ブランコ−ピヤド，
ダニエル ラ，
ダニエル ラ，
ボイド エル． ハリソン，
ボイド エル． ハリソン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sage Therapeutics, LLC
Original Assignee
Sage Therapeutics, LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics, LLC filed Critical Sage Therapeutics, LLC
Publication of JP2021506904A publication Critical patent/JP2021506904A/ja
Priority to JP2023113057A priority Critical patent/JP7689160B2/ja
Priority to JP2025034943A priority patent/JP2025078783A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/002—Expansion of ring A by one atom, e.g. A homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/19—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a saturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/02—Monoamides of sulfuric acids or esters thereof, e.g. sulfamic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/385—Saturated compounds containing a keto group being part of a ring
    • C07C49/487—Saturated compounds containing a keto group being part of a ring containing hydroxy groups
    • C07C49/507—Saturated compounds containing a keto group being part of a ring containing hydroxy groups polycyclic
    • C07C49/513—Saturated compounds containing a keto group being part of a ring containing hydroxy groups polycyclic a keto group being part of a condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J61/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by contraction of only one ring by one or two atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/004—Expansion of ring B by one atom, e.g. B homo steroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/006—Expansion of ring C by one atom, e.g. C homo steroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/40—Ortho- or ortho- and peri-condensed systems containing four condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/40—Ortho- or ortho- and peri-condensed systems containing four condensed rings
    • C07C2603/42—Ortho- or ortho- and peri-condensed systems containing four condensed rings containing only six-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2020534302A 2017-12-22 2018-12-21 Ｃｎｓ障害の処置のための組成物および方法 Withdrawn JP2021506904A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023113057A JP7689160B2 (ja) 2017-12-22 2023-07-10 Ｃｎｓ障害の処置のための組成物および方法
JP2025034943A JP2025078783A (ja) 2017-12-22 2025-03-05 Ｃｎｓ障害の処置のための組成物および方法

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US201762610067P 2017-12-22 2017-12-22
US62/610,067 2017-12-22
US201762611977P 2017-12-29 2017-12-29
US201762612070P 2017-12-29 2017-12-29
US201762612164P 2017-12-29 2017-12-29
US201762612067P 2017-12-29 2017-12-29
US62/612,164 2017-12-29
US62/612,067 2017-12-29
US62/611,977 2017-12-29
US62/612,070 2017-12-29
US201862765164P 2018-08-17 2018-08-17
US62/765,164 2018-08-17
US201862728499P 2018-09-07 2018-09-07
US62/728,499 2018-09-07
US201862737559P 2018-09-27 2018-09-27
US62/737,559 2018-09-27
US201862754977P 2018-11-02 2018-11-02
US62/754,977 2018-11-02
PCT/US2018/067306 WO2019126761A1 (en) 2017-12-22 2018-12-21 Compositions and methods for treating cns disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023113057A Division JP7689160B2 (ja) 2017-12-22 2023-07-10 Ｃｎｓ障害の処置のための組成物および方法

Publications (1)

Publication Number Publication Date
JP2021506904A true JP2021506904A (ja) 2021-02-22

Family

ID=65234664

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020534302A Withdrawn JP2021506904A (ja) 2017-12-22 2018-12-21 Ｃｎｓ障害の処置のための組成物および方法
JP2023113057A Active JP7689160B2 (ja) 2017-12-22 2023-07-10 Ｃｎｓ障害の処置のための組成物および方法
JP2025034943A Pending JP2025078783A (ja) 2017-12-22 2025-03-05 Ｃｎｓ障害の処置のための組成物および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023113057A Active JP7689160B2 (ja) 2017-12-22 2023-07-10 Ｃｎｓ障害の処置のための組成物および方法
JP2025034943A Pending JP2025078783A (ja) 2017-12-22 2025-03-05 Ｃｎｓ障害の処置のための組成物および方法

Country Status (13)

Country Link
US (2) US20220315621A1 (enExample)
EP (1) EP3728285A1 (enExample)
JP (3) JP2021506904A (enExample)
KR (1) KR20200104349A (enExample)
CN (3) CN118085004A (enExample)
AR (1) AR114044A1 (enExample)
AU (2) AU2018392093B2 (enExample)
BR (1) BR112020012761A2 (enExample)
CA (1) CA3086189A1 (enExample)
IL (2) IL275506A (enExample)
MA (1) MA51316A (enExample)
MX (3) MX2020006608A (enExample)
WO (1) WO2019126761A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022538300A (ja) * 2019-06-27 2022-09-01 セージ セラピューティクス， インコーポレイテッド Ｃｎｓ障害を治療するための組成物及び方法
JP2024170487A (ja) * 2019-01-08 2024-12-10 成都康弘薬業集団股▲フン▼有限公司 ステロイド化合物、その使用、およびその調製方法

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2862076C (en) 2012-01-23 2020-04-21 Sage Therapeutics, Inc. Neuroactive steroid formulations and methods of treating cns disorders
PL2887944T3 (pl) 2012-08-21 2022-02-21 Sage Therapeutics, Inc. Allopregnanolon do leczenia lekoopornego stanu padaczkowego
MX362543B (es) 2013-04-17 2019-01-24 Sage Therapeutics Inc Esteroides c21-n-pirazolilo 19-nor c3,3- disustituidos y metodos de uso de los mismos.
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
RS60343B1 (sr) 2014-11-27 2020-07-31 Sage Therapeutics Inc Kompozicije i postupci za lečenje poremećaja cns-a
JOP20190022B1 (ar) 2016-08-23 2023-03-28 Sage Therapeutics Inc ستيرويد 19- نور c3، 3- به استبدال ثنائي لـ c21-n بيرازوليل بلوري
US20200291059A1 (en) 2017-12-08 2020-09-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
AU2018392093B2 (en) 2017-12-22 2024-02-01 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US11718642B2 (en) 2018-01-12 2023-08-08 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
CN114085260B (zh) * 2018-02-11 2023-10-20 江苏豪森药业集团有限公司 甾族类衍生物调节剂、其制备方法和应用
EP4321519A3 (en) 2018-10-12 2024-05-01 Sage Therapeutics, Inc. Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders
TW202521129A (zh) 2018-12-05 2025-06-01 美商賽吉醫療公司 神經活性類固醇及其使用方法
AR119047A1 (es) 2019-05-31 2021-11-17 Sage Therapeutics Inc Esteroides neuroactivos como moduladores de gabaa y su uso en el tratamiento de trastornos del snc
US20230303616A9 (en) * 2019-06-27 2023-09-28 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
CA3143545A1 (en) * 2019-06-27 2020-12-30 Sage Therapeutics, Inc. Compounds for treating cns disorders
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
WO2022246634A1 (en) * 2021-05-25 2022-12-01 Zhejiang Jiachi Development Pharmaceuticals Ltd. Compositions for treating insomnia and uses thereof
CN119306783A (zh) * 2023-07-14 2025-01-14 成都康弘药业集团股份有限公司 一种甾体类化合物的晶型及其用途
CN119529013B (zh) * 2024-11-25 2025-11-07 湖南新合新生物医药有限公司 一种祖拉诺龙中间体的合成方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1380246A (en) * 1970-12-17 1975-01-08 Glaxo Lab Ltd 3alpha-hydroxy-androstanes and esters thereof
JPS5084561A (enExample) * 1973-11-30 1975-07-08
JPS5188953A (en) * 1974-12-23 1976-08-04 Shinki dd homoo20ketoopuregunannoseho
JPS5285159A (en) * 1976-01-06 1977-07-15 Glaxo Lab Ltd Novel steroid compound
JPS52142056A (en) * 1976-04-05 1977-11-26 Glaxo Lab Ltd Production of steroid
GB1581235A (en) * 1977-04-04 1980-12-10 Glaxo Operations Ltd 11a-amino-3a-hydroxy-steroids
WO1998005337A1 (en) * 1996-08-01 1998-02-12 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
JP2016517851A (ja) * 2013-04-17 2016-06-20 セージ セラピューティクス， インコーポレイテッド １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2445161A1 (de) * 1974-09-19 1976-04-01 Schering Ag D-homo-20-ketopregnane ii
US5028631A (en) 1987-11-25 1991-07-02 Schwartz Arthur G Homoandrostan-17-one and homoandrosten-17-ones
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
AU3995595A (en) 1994-12-03 1996-06-26 Dong Kook Pharmaceutical Co., Ltd. Asiatic acid derivatives, its manufacturing method and dermatological agent containing it
WO2002026762A1 (en) 2000-09-29 2002-04-04 Regents Of The University Of Minnesota Triterpenes having antibacterial activity
EP3885352B1 (en) 2014-10-16 2024-11-27 Sage Therapeutics, Inc. A compound, compositions thereof and this compound for use in methods of treating cns disorders
AU2018392093B2 (en) 2017-12-22 2024-02-01 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
KR102821994B1 (ko) * 2019-01-08 2025-06-19 쳉두 캉홍 파마슈티칼 코., 엘티디. 스테로이드 화합물, 및 이의 용도와 제조방법
CN114787174A (zh) 2019-06-27 2022-07-22 萨奇治疗股份有限公司 用于治疗cns病症的组合物和方法

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1380246A (en) * 1970-12-17 1975-01-08 Glaxo Lab Ltd 3alpha-hydroxy-androstanes and esters thereof
JPS5084561A (enExample) * 1973-11-30 1975-07-08
JPS5188953A (en) * 1974-12-23 1976-08-04 Shinki dd homoo20ketoopuregunannoseho
JPS5285159A (en) * 1976-01-06 1977-07-15 Glaxo Lab Ltd Novel steroid compound
JPS52142056A (en) * 1976-04-05 1977-11-26 Glaxo Lab Ltd Production of steroid
GB1581235A (en) * 1977-04-04 1980-12-10 Glaxo Operations Ltd 11a-amino-3a-hydroxy-steroids
WO1998005337A1 (en) * 1996-08-01 1998-02-12 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
JP2016517851A (ja) * 2013-04-17 2016-06-20 セージ セラピューティクス， インコーポレイテッド １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEM. PHARM. BULL., vol. 42, JPN6023000399, 1994, pages 1736 - 1744, ISSN: 0004959519 *
REGISTRY（STN）［ONLINE］, JPN7023000023, 2008, ISSN: 0004959521 *
STEROIDS, vol. 1, JPN6023000398, 1963, pages 664 - 669, ISSN: 0004959520 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024170487A (ja) * 2019-01-08 2024-12-10 成都康弘薬業集団股▲フン▼有限公司 ステロイド化合物、その使用、およびその調製方法
JP7741943B2 (ja) 2019-01-08 2025-09-18 成都康弘薬業集団股▲フン▼有限公司 ステロイド化合物、その使用、およびその調製方法
JP2022538300A (ja) * 2019-06-27 2022-09-01 セージ セラピューティクス， インコーポレイテッド Ｃｎｓ障害を治療するための組成物及び方法
JP7754725B2 (ja) 2019-06-27 2025-10-15 セージ セラピューティクス， インコーポレイテッド Ｃｎｓ障害を治療するための組成物及び方法

Also Published As

Publication number Publication date
MX2023002004A (es) 2023-02-27
CN118772223A (zh) 2024-10-15
AU2018392093B2 (en) 2024-02-01
BR112020012761A2 (pt) 2021-02-17
EP3728285A1 (en) 2020-10-28
CA3086189A1 (en) 2019-06-27
US20220315621A1 (en) 2022-10-06
JP2025078783A (ja) 2025-05-20
JP2023119042A (ja) 2023-08-25
WO2019126761A1 (en) 2019-06-27
JP7689160B2 (ja) 2025-06-05
CN118085004A (zh) 2024-05-28
RU2020123930A (ru) 2022-01-26
IL275506A (en) 2020-08-31
IL323780A (en) 2025-12-01
MA51316A (fr) 2020-10-28
TW201938172A (zh) 2019-10-01
MX2020006608A (es) 2020-11-06
AU2018392093A1 (en) 2020-07-09
CN111741965B (zh) 2024-06-25
US20250171492A1 (en) 2025-05-29
MX2023002006A (es) 2023-02-27
AU2023285947A1 (en) 2024-01-25
CN111741965A (zh) 2020-10-02
AR114044A1 (es) 2020-07-15
KR20200104349A (ko) 2020-09-03
RU2020123930A3 (enExample) 2022-02-04

Similar Documents

Publication Publication Date Title
JP7689160B2 (ja) Ｃｎｓ障害の処置のための組成物および方法
JP7386204B2 (ja) 神経刺激性ステロイド、組成物、およびその使用
JP7065825B2 (ja) Ｃ７、ｃ１２、およびｃ１６置換神経刺激性ステロイドおよびそれらの使用方法
JP7382326B2 (ja) Ｃｎｓ障害の処置のための組成物および方法
JP7538040B2 (ja) ＣＮＳ障害の処置における使用のためのアザ、オキサ、およびチア－プレグナン－２０－オン－３α－オール化合物
CN113166193B (zh) 用于治疗cns病症的在位置10处被环状基团取代的神经活性类固醇
JP2025061798A (ja) Ｃｎｓ障害を治療するための組成物及び方法
BR112021012242A2 (pt) Esteroides neuroativos de 3-alfa-hidróxi-17-beta-amida e composições destes
JP2025060984A (ja) Ｃｎｓ障害を治療するための組成物及び方法
JP2022505146A (ja) ９（１１）－不飽和神経刺激性ステロイド及びそれらの使用方法
RU2799448C2 (ru) Композиции и способы лечения заболеваний центральной нервной системы
RU2810331C2 (ru) Композиции и способы лечения заболеваний центральной нервной системы
CN116685596A (zh) 用于治疗cns病症的组合物和方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230329

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20230724